Alyeska Investment Group
CMPX icon

Alyeska Investment Group’s Compass Therapeutics CMPX Stock Holding History

Alyeska Investment Group’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-545,170
Closed -$2.73M – 465
2022
Q4 		$2.73M Buy
+545,170
New +$2.17M 0.03% 302

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Alyeska Investment Group's CMPX Position: Q1 2023 in Review

Alyeska Investment Group sold out of Compass Therapeutics (CMPX) in Q1 2023, closing a stake of 545,170 shares — an estimated $2.73M sold.

Alyeska Investment Group first reported a position in CMPX in Q4 2022 and held it in 1 quarter. The position peaked at $2.73M in Q4 2022. 72 funds tracked by Wall St. Rank hold CMPX as of Q1 2023.

  • Alyeska Investment Group reported no remaining Compass Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Alyeska Investment Group sold 545,170 Compass Therapeutics shares in Q1 2023, an estimated $2.73M.
  • Alyeska Investment Group first reported a position in Compass Therapeutics in Q4 2022 and held it in 1 quarter.
  • Alyeska Investment Group's Compass Therapeutics position peaked at $2.73M in Q4 2022.
  • 72 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2023.

Based on Alyeska Investment Group's 13F filing for Q1 2023, filed 15 May 2023.